ASCO Congress — a significat progress in the patient’s treatment with esophageal cancer 

Home - News

On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.


Last news

UAE National Day 2023

Celebrated every year on November 21, UAE National Day is one of the country’s most eagerly awaited public holidays. This year, the UAE has celebrated its 52nd anniversary.

Read more »